secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001193125-25-157364
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stoke/Biogen present zorevunersen Phase 3 EMPEROR analysis showing cognition/behavior improvements at Week 68
--------------------------------------------------------------------------------

- Analysis of patients on EMPEROR-like regimen (2x70mg loading + 2x45mg maintenance) showed cognition/behavior improvements at Week 68.
- Results contrast with natural history (BUTTERFLY) where standard-of-care patients did not show improvements.
- Five Vineland-3 sub-domains (Receptive/Expressive Communication, Interpersonal Relationships, Coping/Personal Skills) added as key secondary endpoints in Phase 3 EMPEROR.
- Data complement prior Phase 1/2a and OLE results showing durable seizure reductions and improvements through two years.
- Zorevunersen is a first-in-class potential disease-modifying RNA medicine for Dravet syndrome co-developed with Biogen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312525157364/0001193125-25-157364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312525157364/d873782d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-157364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer